Lymphoma
NCI scientist receives Samuel D. Gross Prize for surgical research
Renowned cancer researcher Steven A. Rosenberg, MD, PhD, has been awarded the 2020 Samuel D. Gross Prize for surgical research.
Late effects of Hodgkin lymphoma treatment: We can still do better
In more than 6 years as a chief medical editor for HemOnc Today, only a few subjects have prompted me to write more than one editorial.
Lisocabtagene maraleucel could be ‘CAR T-cell treatment of choice’ for lymphoma subset
Nearly three-quarters of patients who received lisocabtagene maraleucel for relapsed or refractory large B-cell lymphoma achieved objective response, according to results of the TRANSCEND NHL 001 trial published in The Lancet.
Trial to test acalabrutinib for patients with blood cancer, COVID-19
The increasing number of deaths in the United States due to COVID-19 has underscored the need to identify populations at elevated risk for virus-related mortality.
FDA grants fast track designation to ‘switchable’ CAR-T for B-cell malignancies
The FDA granted fast track designation to CLBR001 + SWI019, a chimeric antigen receptor T-cell therapy designed to treat B-cell malignancies, according to the agent’s developer.
Getting to the heart of CAR T-cell therapy’s cardiovascular risks
How much risk is too much? It depends on what is at stake.
CAR-T plus pembrolizumab shows ‘superior’ safety, promising responses in advanced lymphoma
No patients who received pembrolizumab with a CD19/CD22-directed chimeric antigen receptor T-cell therapy experienced high-grade cytokine release syndrome, according to phase 1 study findings presented during ESMO Virtual Congress 2020.
FDA grants priority review to Xalkori for certain children with lymphoma
The FDA granted priority review to crizotinib for the treatment of certain children with lymphoma, according to the agent’s manufacturer.
Neurotoxicity after CAR T-cell therapy has no effect on survival in lymphoma subset
Development of immune effector cell-associated neurotoxicity syndrome did not negatively affect survival outcomes among patients treated with axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma, study results showed.
HIV status does not affect outcomes in advanced classical Hodgkin lymphoma
HIV status did not affect outcomes after first-line chemotherapy for patients with advanced classical Hodgkin lymphoma, according to study results presented at Society of Hematologic Oncology Annual Meeting.